Home » Stocks » PAND

Pandion Therapeutics, Inc. (PAND)

Stock Price: $60.87 USD 0.67 (1.11%)
Updated Mar 1, 2021 2:46 PM EST - Market open
Market Cap 1.78B
Revenue (ttm) 7.56M
Net Income (ttm) n/a
Shares Out 23.27M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $60.87
Previous Close $60.20
Change ($) 0.67
Change (%) 1.11%
Day's Open 60.20
Day's Range 59.96 - 60.99
Day's Volume 244,009
52-Week Range 10.28 - 60.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 days ago

NEW YORK, Feb. 27, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities...

PRNewsWire - 3 days ago

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Pandion Therapeutics, Inc. (NASDAQ: PAND) co...

Benzinga - 3 days ago

Pandion Therapeutics Inc (NASDAQ: PAND) shares closed over 133% higher today. What Happened: Pandion — a developer of novel therapeutics targeting autoimmune diseases — will be acquired by a s...

The Motley Fool - 3 days ago

You'd vault into the air too if a big-name pharmaceutical paid a high premium for your stock.

GuruFocus - 3 days ago

Seeking to beef up a product line dominated by the cancer drug Keytruda, Merck & Co. Inc. (NYSE:MRK) has made another in a series of acquisitions. The Kenilworth, New Jersey-based drug giant i...

Other stocks mentioned: MRK
Investors Business Daily - 3 days ago

Pandion Therapeutics stock blasted to a record high Thursday on Merck's plan to buy the IPO stock for $1.85 billion. Pandion just recently wrapped its initial public offering in July.

Other stocks mentioned: MRK
PRNewsWire - 3 days ago

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pandion Therapeutics, Inc. ("...

GlobeNewsWire - 4 days ago

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Pa...

Other stocks mentioned: MRK
Business Wire - 4 days ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Pandion Therapeutics, Inc. (NASDAQ: PAND) to Merck is fair to Pandion share...

InvestorPlace - 4 days ago

Pandion Therapeutics (PAND) stock is soaring higher on Thursday after announcing that Merck (MRK) plans to acquire the biotechnology company. The post PAND Stock: Why Pandion Therapeutics Shar...

Investors Business Daily - 4 days ago

Pandion Therapeutics stock blasted to a record high Thursday on Merck's plan to buy the IPO stock for $1.85 billion. Pandion just recently wrapped its initial public offering in July.

Other stocks mentioned: MRK
Forbes - 4 days ago

Pharma deals slowed down last year partly due to Covid impact.

Other stocks mentioned: MRK
GlobeNewsWire - 1 week ago

WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unme...

GlobeNewsWire - 1 week ago

WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unme...

GlobeNewsWire - 1 month ago

-Phase 1a trial achieved primary objective of safety and tolerability -PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in t...

GlobeNewsWire - 2 months ago

WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unme...

GlobeNewsWire - 3 months ago

- Enrollment and dosing complete in Phase 1a clinical trial of PT101 ; top-line results expected early 2021 - PT627 s ystemic PD-1 agonist development candidate nominated; IND-enabling studies...

GlobeNewsWire - 3 months ago

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unme...

GlobeNewsWire - 4 months ago

WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unme...

GlobeNewsWire - 5 months ago

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the u...

GlobeNewsWire - 5 months ago

WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the u...

GlobeNewsWire - 6 months ago

- Completed successful IPO providing approximately $153 million in gross proceeds; cash runway extended through first half of 2024

Market Watch - 7 months ago

Pandion Therapeutics Inc. PAND, +37.77% started its public life with a bang, as biotechnology company's stock opened 50% above where the upsized initial public offering was priced.

Market Watch - 7 months ago

Pandion Therapeutics Inc. raised more than expected in its initial public offering, which was upsized to 7.5 million shares and priced at $18.

About PAND

Pandion Therapeutics, a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 17, 2020
CEO
Dr. Rahul Kakkar
Stock Exchange
NASDAQ
Ticker Symbol
PAND
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PAND stock is "Buy." The 12-month stock price forecast is 42.50, which is a decrease of -30.18% from the latest price.

Price Target
$42.50
(-30.18% downside)
Analyst Consensus: Buy